UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):  June 9, 2016

 

CELLCEUTIX CORPORATION

(Exact Name of Registrant as Specified in Charter)

 

Nevada

001-37357

30-0565645

(State or Other Jurisdiction

(Commission File Number)

(IRS Employer

of Incorporation)

Identification No.)

  

100 Cummings Center, Suite 151-B
Beverly, Massachusetts

01915

(Address of Principal Executive Offices)

(Zip Code)

 

Registrant's telephone number, including area code: (978) 921-4125

 

__________________________________________________

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On June 9, 2016, Cellceutix Corporation (the "Company") issued a press release announcing the dismissal of the securities class action lawsuit brought against the Company in the United States District Court for the Southern District of New York by the Rosen Law Firm. The full text of the press release is furnished with this Form 8-K as Exhibit 99.1 and incorporated by reference herein.

 

The information in this Current Report on Form 8-K under Item 7.01, including the accompanying press release, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by reference to such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.

Description

 

99.1

Press Release dated June 9, 2016.

 

 
2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CELLCEUTIX CORPORATION

 

       
Dated: June 9, 2016 By: /s/ Leo Ehrlich

 

 

 

Leo Ehrlich

 

 

 

Chief Executive Officer and Chief Financial Officer

 

 

 

 

 

 

 3

 

 

Exhibit Index

 

Exhibit No.

Description

 

99.1

Press Release dated June 9, 2016.

 

 

4

Innovation Pharmaceuticals (CE) (USOTC:IPIX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Innovation Pharmaceuticals (CE) Charts.
Innovation Pharmaceuticals (CE) (USOTC:IPIX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Innovation Pharmaceuticals (CE) Charts.